Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Apatinib in TP53-Mutated Solid Tumors
NCT03645200Phase 1Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluzoparib and Rivoceranib, sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
fluzoparibRivoceranib
Beyond the preview
Go deeper on NCT03645200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645200.